(RTTNews) - Medical technology company Boston Scientific Corp. (BSX) announced Tuesday that it has received U.S. Food and Drug Administration approval for expanded labeling of WATCHMAN FLX Left Atrial ...

On Saturday, Boston Scientific Corporation (NYSE:BSX) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

Expanding its Interventional Cardiology (IC) suite, Boston Scientific CorporationBSX recently announced receipt of the CE Mark for the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) device. At the ...

The WATCHMAN™ LAAC Device is designed to close the left atrial appendage (LAA) in order to prevent the migration of blood clots and the strokes that could follow. BOSTON SCIENTIFIC A device built by ...

New data presented at the Cardiovascular Research Technologies (CRT) 2023 meeting reinforced the safety and effectiveness of Boston Scientific Corp.’s Watchman FLX left atrial appendage occlusion ...

Boston Scientific Corporation today announced it has received FDA approval to expand the instructions for use in labeling the current-generation WATCHMAN FLX Left Atrial Appendage Closure (LAAC) ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...